{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:54:57Z","timestamp":1789512897163,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,5,6]],"date-time":"2015-05-06T00:00:00Z","timestamp":1430870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s00198-015-3148-4","type":"journal-article","created":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T07:53:47Z","timestamp":1430812427000},"page":"2355-2363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"26","author":[{"given":"L.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,6]]},"reference":[{"key":"3148_CR1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/8756-3282(93)90189-H","volume":"14","author":"MS Shih","year":"1993","unstructured":"Shih MS, Cook MA, Spence CA, Palnitkar S, McElroy H, Parfitt AM (1993) Relationship between bone formation rate and osteoblast surface on different subdivisions of the endosteal envelope in aging & osteoporosis. Bone 14:519\u2013521","journal-title":"Bone"},{"key":"3148_CR2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00393-010-0739-5","volume":"70","author":"D Boluki","year":"2011","unstructured":"Boluki D (2011) Surgical therapy of osteoporotic vertebral body fractures. Z Rheumatol 70:45\u201355","journal-title":"Z Rheumatol"},{"issue":"4","key":"3148_CR3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00223-001-1043-9","volume":"69","author":"LJ Melton 3rd","year":"2001","unstructured":"Melton LJ 3rd (2001) The prevalence of osteoporosis: gender and racial comparison. Calcif Tissue Int 69(4):179\u2013181","journal-title":"Calcif Tissue Int"},{"issue":"9156","key":"3148_CR4","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156):878\u2013882","journal-title":"Lancet"},{"issue":"1","key":"3148_CR5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1359\/jbmr.1999.14.1.57","volume":"14","author":"EM Colin","year":"1999","unstructured":"Colin EM, Van Den Bemd GJ, Van Aken M, Christakos S, De Jonge HR, Deluca HF, Prahl JM, Birkenh\u00e4ger JC, Buurman CJ, Pols HA, Van Leeuwen JP (1999) Evidence for involvement of 17beta-estradiol in intestinal calcium absorption independent of 1, 25-dihydroxyvitamin D3 level in the rat. J Bone Miner Res 14(1):57\u201364","journal-title":"J Bone Miner Res"},{"issue":"5","key":"3148_CR6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333\u2013340","journal-title":"N Engl J Med"},{"issue":"18","key":"3148_CR7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809\u20131822","journal-title":"N Engl J Med"},{"issue":"1","key":"3148_CR8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83\u201391","journal-title":"Osteoporos Int"},{"issue":"5","key":"3148_CR9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","volume":"65","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2\u00a0year results from the MOBILE study. Ann Rheum Dis 65(5):654\u2013661","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3148_CR10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"KG Saag","year":"1998","unstructured":"Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339(5):292\u2013299","journal-title":"N Engl J Med"},{"issue":"24","key":"3148_CR11","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077\u20132082","journal-title":"JAMA"},{"key":"3148_CR12","unstructured":"Reclast Prescribing Information. Novartis Pharma Stein AG; Stein, Switzerland. Available at: http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/reclast.pdf Accessed Nov 2, 2014"},{"key":"3148_CR13","unstructured":"Actonel (risedronate sodium tablets) US prescribing information. Procter and Gamble Pharmaceuticals; Cincinnati, OH. Available at: https:\/\/www.actonel.com\/global\/prescribing_information.pdf .Accessed Nov 2, 2014"},{"key":"3148_CR14","unstructured":"Fosamax (alendronate sodium) US prescribing information. Merck and Co., Inc.; Whitehouse Station, NJ. Available at: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/f\/fosamax\/fosamax_pi.pdf .Accessed Nov 2, 2014"},{"issue":"9","key":"3148_CR15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343(9):604\u2013610","journal-title":"N Engl J Med"},{"issue":"2","key":"3148_CR16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00223-002-1085-7","volume":"73","author":"S Gonnelli","year":"2003","unstructured":"Gonnelli S, Cepollaro C, Montagnani A, Bruni D, Caffarelli C, Breschi M, Gennari L, Gennari C, Nuti R (2003) Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 73(2):133\u2013139","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"3148_CR17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00774-009-0136-9","volume":"28","author":"JS Hwang","year":"2010","unstructured":"Hwang JS, Liou MJ, Ho C, Lin JD, Huang YY, Wang CJ, Tsai KS, Chen JF (2010) The effects of weekly alendronate therapy in Taiwanese males with osteoporosis. J Bone Miner Metab 28(3):328\u2013333. doi: 10.1007\/s00774-009-0136-9","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"3148_CR18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00296-003-0388-y","volume":"24","author":"JD Ringe","year":"2004","unstructured":"Ringe JD, Dorst A, Faber H, Ibach K (2004) Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24(2):110\u2013113","journal-title":"Rheumatol Int"},{"issue":"4","key":"3148_CR19","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3349\/ymj.2009.50.4.474","volume":"50","author":"J Iwamoto","year":"2009","unstructured":"Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H (2009) Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures. Yonsei Med J 50(4):474\u2013481","journal-title":"Yonsei Med J"},{"issue":"4","key":"3148_CR20","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1359\/jbmr.081214","volume":"24","author":"S Boonen","year":"2009","unstructured":"Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD (2009) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24(4):719\u2013725","journal-title":"J Bone Miner Res"},{"issue":"5","key":"3148_CR21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00296-005-0004-4","volume":"26","author":"JD Ringe","year":"2006","unstructured":"Ringe JD, Faber H, Farahmand P, Dorst A (2006) Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 26(5):427\u2013431","journal-title":"Rheumatol Int"},{"issue":"18","key":"3148_CR22","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","volume":"367","author":"S Boonen","year":"2012","unstructured":"Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367(18):1714\u20131723","journal-title":"N Engl J Med"},{"issue":"4","key":"3148_CR23","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.bone.2009.12.034","volume":"46","author":"ES Orwoll","year":"2010","unstructured":"Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G (2010) Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46(4):970\u2013976","journal-title":"Bone"},{"key":"3148_CR24","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1097\/BRS.0b013e3181b1c99f","volume":"34","author":"AD Furlan","year":"2009","unstructured":"Furlan AD, Pennick V, Bombardier C, van Tulder M, Editorial Board, Cochrane Back Review Group (2009) 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976) 34:1929\u20131941","journal-title":"Spine (Phila Pa 1976)"},{"issue":"10","key":"3148_CR25","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1007\/s11999-012-2404-6","volume":"470","author":"MM Shi","year":"2012","unstructured":"Shi MM, Cai XZ, Lin T, Wang W, Yan SG (2012) Is there really no benefit of vertebroplasty for osteoporotic vertebral fractures? A meta-analysis. Clin Orthop Relat Res 470(10):2785\u20132799","journal-title":"Clin Orthop Relat Res"},{"key":"3148_CR26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1472-6963-5-25","volume":"5","author":"D Atkins","year":"2005","unstructured":"Atkins D, Briss PA, Eccles M, Flottorp S, Guyatt GH, Harbour RT, Hill S, Jaeschke R, Liberati A, Magrini N, Mason J, O\u2019Connell D, Oxman AD, Phillips B, Sch\u00fcnemann H, Edejer TT, Vist GE, Williams JW Jr, Working Group GRADE (2005) Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res 5:25","journal-title":"BMC Health Serv Res"},{"issue":"7414","key":"3148_CR27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"18","key":"3148_CR28","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, Recurrent Fracture Trial HORIZON (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799\u20131809","journal-title":"N Engl J Med"},{"key":"3148_CR29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bone.2013.09.023","volume":"58","author":"EF Eriksen","year":"2014","unstructured":"Eriksen EF, D\u00edez-P\u00e9rez A, Boonen S (2014) Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone 58:126\u2013135","journal-title":"Bone"},{"issue":"10","key":"3148_CR30","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359\u20132381","journal-title":"Osteoporos Int"},{"issue":"5","key":"3148_CR31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1759720X13500861","volume":"5","author":"PR Sim IeW Ebeling","year":"2013","unstructured":"Sim IeW Ebeling PR (2013) Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence. Ther Adv Musculoskelet Dis 5(5):259\u2013267","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"3148_CR32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/BOR.0b013e328362164d","volume":"25","author":"PR Ebeling","year":"2013","unstructured":"Ebeling PR (2013) Osteoporosis in men. Curr Opin Rheumatol 25(4):542\u2013552","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"3148_CR33","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00002512-200522090-00003","volume":"22","author":"HK Kamel","year":"2005","unstructured":"Kamel HK (2005) Male osteoporosis: new trends in diagnosis and therapy. Drugs Aging 22(9):741\u2013748","journal-title":"Drugs Aging"},{"key":"3148_CR34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2474-6-39","volume":"6","author":"AM Sawka","year":"2005","unstructured":"Sawka AM, Papaioannou A, Adachi JD, Gafni A, Hanley DA, Thabane L (2005) Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 6:39","journal-title":"BMC Musculoskelet Disord"},{"issue":"10","key":"3148_CR35","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/jbmr.119","volume":"25","author":"ES Orwoll","year":"2010","unstructured":"Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS (2010) Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5\u00a0mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25(10):2239\u20132250","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3148-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-015-3148-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-015-3148-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:15:23Z","timestamp":1558610123000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-015-3148-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,6]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["3148"],"URL":"https:\/\/doi.org\/10.1007\/s00198-015-3148-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,6]]}}}